|1.||Bril, Vera: 5 articles (07/2009 - 10/2004)|
|2.||Matsumoto, Takafumi: 4 articles (01/2014 - 07/2008)|
|3.||Giannoukakis, Nick: 3 articles (07/2014 - 10/2006)|
|4.||Kakehashi, Akihiro: 2 articles (01/2014 - 01/2013)|
|5.||Tsuji, Junichi: 2 articles (01/2014 - 01/2013)|
|6.||Kinoshita, Nozomi: 2 articles (01/2014 - 01/2013)|
|7.||Ota, Ayumi: 2 articles (01/2014 - 01/2013)|
|8.||Takano, Hiroko: 2 articles (01/2014 - 01/2013)|
|9.||Toyoda, Fumihiko: 2 articles (01/2014 - 01/2013)|
|10.||Kuromiya, Akemi: 2 articles (07/2008 - 07/2008)|
07/01/2009 - "We aimed to determine whether ranirestat, an ARI, could slow or reverse the course of diabetic sensorimotor polyneuropathy (DSP). "
07/01/2009 - "Ranirestat for the management of diabetic sensorimotor polyneuropathy."
01/01/2006 - "Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy."
01/01/2006 - "We aimed to determine whether ranirestat, an aldose reductase inhibitor, maintains the improved nerve function observed in patients with diabetic sensorimotor polyneuropathy (DSP) after completing a 12-week nerve biopsy study. "
07/01/2008 - "Ranirestat (AS-3201) is a novel aldose reductase (AR) inhibitor with potentially beneficial effects on diabetic sensorimotor polyneuropathy. "
04/01/2008 - "Ranirestat is safe, exhibits some efficacy and is perhaps the only agent advanced enough in clinical trials to warrant further consideration for diabetic complications."
07/01/2014 - "The objective of this evaluation is to summarize and provide expert opinion on the status of ranirestat with an emphasis on its pharmacokinetics in the context of its potential effects to prevent/treat diabetic complications. "
04/01/2008 - "Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications."
10/01/2006 - "Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications."
04/01/2014 - "Currently, aldose reductase inhibitors like epalrestat, ranirestat and fidarestat are used for the amelioration of diabetic complications. "
|3.||Diabetic Neuropathies (Diabetic Neuropathy)
07/01/2014 - "Evaluation of ranirestat for the treatment of diabetic neuropathy."
07/01/2008 - "Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats."
07/01/2014 - "A qualitative systematic literature search of PubMed through November 2013 using MeSH terms - aldose reductase inhibitors, diabetic neuropathy, AS-3201, ranirestat, diabetic complications and pharmacokinetics/pharmacodynamics - identified relevant publications limited to human and rodent (mouse and rat) and English-language studies. "
07/01/2008 - "However, in the ranirestat-treated diabetic rats, no lens opacity was observed in any rat throughout the entire experimental period. "
01/01/2013 - "Ranirestat prevents DN and cataract; epalrestat prevents DN only."
01/01/2013 - "Ranirestat significantly (P < 0.01) inhibited rapid cataract development; epalrestat did not. "
01/01/2013 - "Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats."
07/01/2008 - "Sorbitol levels in the sciatic nerve and lens, motor nerve conduction velocity (MNCV), and development of cataracts were measured in STZ-diabetic rats given a ranirestat-admixed diet (0.0005%) for 35 weeks. "
|5.||Diabetic Retinopathy (Retinopathy, Diabetic)
|1.||Aldehyde Reductase (Aldose Reductase)
|5.||ONO 2235 (epalrestat)
|7.||Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)